Jan 29, 2015 | Anti-METH antibody, IXT-m200, Anti-METH Vaccine, General News, Grants, Uncategorized
LITTLE ROCK – A University of Arkansas for Medical Sciences (UAMS) BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break...
Jan 5, 2015 | Anti-METH antibody, IXT-m200, General News, Uncategorized
The company is pleased to report publication of the results of the first human study of ch-mAb7F9. The paper was published in the journal Mabs in early November. Abstract – This first-in-human study examined the safety and pharmacokinetics of ch-mAb7F9, an...
Recent Comments